Electron microscopy studies of novel poliovirus genome-releasing intermediates

新型脊髓灰质炎病毒基因组释放中间体的电子显微镜研究

基本信息

  • 批准号:
    7906887
  • 负责人:
  • 金额:
    $ 5.22万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2009
  • 资助国家:
    美国
  • 起止时间:
    2009-08-01 至 2011-07-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Picornaviruses are non-enveloped viruses and cannot rely on fusion of a viral membrane with a host cell membrane to gain access to the cytoplasm. They rely on the ability of capsid proteins to undergo as-yet-uncharacterized conformational changes for the viral RNA to breach the host-membrane barrier. These irreversible changes include externalization of peptides from the interior of the capsid shell. Poliovirus is the prototypical picornavirus and serves as an excellent model system. Our broad aim is to gain knowledge of viral structural dynamics associated with host-membrane attachment and genome release by using electron microscopy and three-dimensional data analysis (3DEM). The picornaviruses share a high degree of structural homology with one another and, therefore, the models and methodologies developed during this study will be relevant to other picornaviruses. The two specific aims of this proposed study are 1) to determine the 3DEM structures of poliovirus intermediates during genome-release, and 2) to determine 3DEM structures of such intermediates attached to liposomes. The experimental steps to be carried out are listed below: a. Optimize conditions for preparing vitrified EM grids enriched with poliovirus particles at a particular stage (early or late) of RNA-release. b. Collect EM data (both un-tilted and tomographic) using the Polara and Tecnai F30 microscopes. c. Determine both icosahedral and asymmetric 3D reconstructions of RNA-release intermediates from the 2D EM images using the program PFT for un-tilted data and IMOD for tomograms. d. Build pseudo-atomic models to fit the higher-resolution EM maps, to help account for density changes. PUBLIC HEALTH RELEVANCE: The Picornavirus family includes cardioviruses, foot-and-mouth disease virus, rhinoviruses, hepatitis A virus and enteroviruses. Among these, there are significant causes of human and veterinary diseases. Detailed knowledge of the molecular mechanisms that these viruses use for membrane attachment and genome release would help in the development of antiviral strategies to block the earliest stages of infection and reduce pathogenicity.
描述(由申请人提供):小核糖核酸病毒是非包膜病毒,不能依靠病毒膜与宿主细胞膜的融合来进入细胞质。它们依靠衣壳蛋白的能力来经历尚未表征的构象变化,从而使病毒RNA突破宿主膜屏障。这些不可逆的变化包括多肽从衣壳内部外化。脊髓灰质炎病毒是典型的小核糖核酸病毒,是一个很好的模型系统。我们的主要目标是通过使用电子显微镜和三维数据分析(3DEM)来获得与宿主膜附着和基因组释放相关的病毒结构动力学知识。这些小核糖核酸病毒彼此具有高度的结构同源性,因此,在本研究中开发的模型和方法将与其他小核糖核酸病毒相关。本研究的两个具体目的是:1)确定脊髓灰质炎病毒中间体在基因组释放过程中的3DEM结构;2)确定这些中间体附着在脂质体上的3DEM结构。要进行的实验步骤如下:a.优化在rna释放的特定阶段(早期或晚期)制备富含脊髓灰质炎病毒颗粒的玻璃化EM网格的条件。b.使用Polara和Tecnai F30显微镜收集EM数据(非倾斜和层析)。c.使用PFT程序(非倾斜数据)和IMOD程序(断层图)确定2D EM图像中rna释放中间体的二十面体和不对称3D重建。d.建立伪原子模型,以适应更高分辨率的电磁图,以帮助解释密度的变化。公共卫生相关性:小核糖核酸病毒家族包括心脏病毒、口蹄疫病毒、鼻病毒、甲型肝炎病毒和肠道病毒。其中,有人类和兽医疾病的重要原因。详细了解这些病毒用于膜附着和基因组释放的分子机制将有助于开发抗病毒策略,以阻断感染的早期阶段并降低致病性。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

HAZEL C LEVY其他文献

HAZEL C LEVY的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

相似海外基金

Development of a new generation of antiviral agents that are effective against drug-resistant viruses and prevent serious illness and sequelae.
开发新一代抗病毒药物,可有效对抗耐药病毒并预防严重疾病和后遗症。
  • 批准号:
    23K18186
  • 财政年份:
    2023
  • 资助金额:
    $ 5.22万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
A versatile structure-based therapeutic platform for development of VHH-based antitoxin and antiviral agents
一个多功能的基于结构的治疗平台,用于开发基于 VHH 的抗毒素和抗病毒药物
  • 批准号:
    10560883
  • 财政年份:
    2023
  • 资助金额:
    $ 5.22万
  • 项目类别:
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
  • 批准号:
    10730692
  • 财政年份:
    2021
  • 资助金额:
    $ 5.22万
  • 项目类别:
Design and synthesis of nucleosides to develop antiviral agents and oligonucleotide therapeutics
设计和合成核苷以开发抗病毒药物和寡核苷酸疗法
  • 批准号:
    21K06459
  • 财政年份:
    2021
  • 资助金额:
    $ 5.22万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
  • 批准号:
    10189880
  • 财政年份:
    2021
  • 资助金额:
    $ 5.22万
  • 项目类别:
Computer-aided identification and synthesis of novel broad-spectrum antiviral agents
新型广谱抗病毒药物的计算机辅助鉴定和合成
  • 批准号:
    2404261
  • 财政年份:
    2020
  • 资助金额:
    $ 5.22万
  • 项目类别:
    Studentship
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10222540
  • 财政年份:
    2020
  • 资助金额:
    $ 5.22万
  • 项目类别:
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10669717
  • 财政年份:
    2020
  • 资助金额:
    $ 5.22万
  • 项目类别:
Association between sedentary lifestyle and liver cancer development in hepatitis C patients treated with direct-acting antiviral agents
接受直接抗病毒药物治疗的丙型肝炎患者久坐的生活方式与肝癌发展之间的关系
  • 批准号:
    20K10713
  • 财政年份:
    2020
  • 资助金额:
    $ 5.22万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10174522
  • 财政年份:
    2020
  • 资助金额:
    $ 5.22万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了